AUPH Aurinia Pharmaceuticals Quick Ratio

Regular sales of the core drug create a steady cash flow, although relying on a single product increases financial risks. Current operating income is delivering tangible results, while the potential for mergers with other players remains on hold for now. The indicator stands at 4.75. This trading chart refers to Aurinia Pharmaceuticals (AUPH), the developer of the first oral treatment for lupus nephritis.

An investment audit of Aurinia Pharmaceuticals (AUPH) requires a rigorous solvency assessment via the ratio of cash and accounts receivable to current liabilities, excluding inventories. An analysis of the quick ratio on GURU.Markets allows for an evaluation of how effectively Aurinia Pharmaceuticals (AUPH) finances the expansion of Lupkynis and the scaling of distribution by relying on liquid assets rather than hard-to-liquidate inventory.